Astal Laboratories Ltd — Important, 10-10-2025: Company Update

Astal Laboratories' board has approved a preferential issue of 3,04,58,187 new equity shares, valued at approximately Rs. 277.17 crore. These shares, priced at Rs. 91 each (face value Rs. 10, premium Rs. 81), will be issued to 135 investors. This share issuance is for the acquisition of 100% equity in Sriven Pharmachem India Private Limited. This strategic move, contingent on shareholder approval, aims to expand Astal Laboratories' business by integrating Sriven Pharmachem, signifying inorganic growth for the company.